Ylbe Palacios de Franco1, Karina Velazquez2, Natalia Segovia3, Carolina Acosta4, Deborah Yanosky4, Ylbe V Franco Palacios5, Amanda Ramos6, Carlos R Franco Palacios7. 1. Catholic University of Asuncion School of Medicine Asuncion, Paraguay ; Department of Obstetrics and Gynecology, Instituto de Prevision Social (IPS) Hospital Asuncion, Paraguay. 2. Department of Laboratory Medicine, Instituto de Prevision Social (IPS) Hospital Asuncion, Paraguay. 3. Department of Clinical Immunology, Instituto de Prevision Social (IPS) Hospital Asuncion, Paraguay. 4. Department of Obstetrics and Gynecology, Instituto de Prevision Social (IPS) Hospital Asuncion, Paraguay. 5. Department of Obstetrics and Gynecology, Complete Care Health Network, South Jersey General Hospital Vineland, NJ. USA. 6. Department of Gynecology and Obstetrics, Johns Hopkins Hospital Baltimore, MD. USA. 7. Department of Nephrology, Affiliated Community Medical Centers, Rice Memorial Hospital Willmar, MN. USA.
Abstract
BACKGROUND: Preeclampsia is associated with significant materno-fetal morbidity and mortality. Podocyturia due to podocyte damage seems to be associated with the disease. The objective of this study was to evaluate the usefulness of urinary podocalyxin as a marker of preeclampsia in a Hispanic population. METHODS: 63 patients were studied. 25 patients had preeclampsia/eclampsia (PE-E). 38 patients had normal pregnancies and served as control group. 24 hour proteinuria, urine protein/creatinine (UPC), urinary podocalyxin and perinatal outcomes were measured. A Podocalyxin ELISA test was used to detect podocyturia. RESULTS: Mean age (years), mean±SD was 30.5±5.4 in normal patients vs 30.6±5.8 in PE-E, p=0.98. Median gestational age (weeks) was, 38 (range 21-42) for normal pregnancies and 36 (range 24-40) for patients with PE-E, <0.001. Urine podocalyxin/creatinine on admission (ng/mg), median [IQR] in normal patients was 55.9 [29.4, 74.9] vs 109.7 [63.8, 234.1] in PE-E, p=0.001. After adjusting for admission proteinuria, urinary podocalyxin remained independently associated with preeclampsia: OR=1.0040 (95% CI 1.0003-1.0078), p=0.03. There was low to moderate correlation between UPC and urinary podocalyxin, Spearman's =0.31, p=0.01. In PE-E, post-partum urine podocalyxin was lower, median [IQR]: 69.7 [32.7, 184.8] p=0.19 vs admission. There was a trend towards more podocyturia and proteinuria in patients with eclampsia, comparing to those with preeclampsia. There was no association observed between podocyturia and neonatal mortality, IUGR or Apgar scores. CONCLUSIONS: Significantly higher levels of urinary podocalyxin are seen in preeclampsia/eclampsia. They tend to normalize after delivery.
BACKGROUND: Preeclampsia is associated with significant materno-fetal morbidity and mortality. Podocyturia due to podocyte damage seems to be associated with the disease. The objective of this study was to evaluate the usefulness of urinary podocalyxin as a marker of preeclampsia in a Hispanic population. METHODS: 63 patients were studied. 25 patients had preeclampsia/eclampsia (PE-E). 38 patients had normal pregnancies and served as control group. 24 hour proteinuria, urine protein/creatinine (UPC), urinary podocalyxin and perinatal outcomes were measured. A Podocalyxin ELISA test was used to detect podocyturia. RESULTS: Mean age (years), mean±SD was 30.5±5.4 in normal patients vs 30.6±5.8 in PE-E, p=0.98. Median gestational age (weeks) was, 38 (range 21-42) for normal pregnancies and 36 (range 24-40) for patients with PE-E, <0.001. Urine podocalyxin/creatinine on admission (ng/mg), median [IQR] in normal patients was 55.9 [29.4, 74.9] vs 109.7 [63.8, 234.1] in PE-E, p=0.001. After adjusting for admission proteinuria, urinary podocalyxin remained independently associated with preeclampsia: OR=1.0040 (95% CI 1.0003-1.0078), p=0.03. There was low to moderate correlation between UPC and urinary podocalyxin, Spearman's =0.31, p=0.01. In PE-E, post-partum urine podocalyxin was lower, median [IQR]: 69.7 [32.7, 184.8] p=0.19 vs admission. There was a trend towards more podocyturia and proteinuria in patients with eclampsia, comparing to those with preeclampsia. There was no association observed between podocyturia and neonatal mortality, IUGR or Apgar scores. CONCLUSIONS: Significantly higher levels of urinary podocalyxin are seen in preeclampsia/eclampsia. They tend to normalize after delivery.
Authors: Garabed Eknoyan; Thomas Hostetter; George L Bakris; Lee Hebert; Andrew S Levey; Hans-Henrik Parving; Michael W Steffes; Robert Toto Journal: Am J Kidney Dis Date: 2003-10 Impact factor: 8.860
Authors: Tim P Kelder; Marlies E Penning; Hae-Won Uh; Danielle Cohen; Kitty W M Bloemenkamp; Jan A Bruijn; Sicco A Scherjon; Hans J Baelde Journal: Hypertension Date: 2012-10-22 Impact factor: 10.190
Authors: Iasmina M Craici; Steven J Wagner; Kent R Bailey; Patrick D Fitz-Gibbon; Christina M Wood-Wentz; Stephen T Turner; Suzanne R Hayman; Wendy M White; Brian C Brost; Carl H Rose; Joseph P Grande; Vesna D Garovic Journal: Hypertension Date: 2013-03-25 Impact factor: 10.190
Authors: M Hara; T Yamamoto; T Yanagihara; T Takada; M Itoh; Y Adachi; A Yoshizumi; K Kawasaki; I Kihara Journal: Nephron Date: 1995 Impact factor: 2.847
Authors: Kate Bramham; Carlos E Poli-de-Figueiredo; Paul T Seed; Annette L Briley; Lucilla Poston; Andrew H Shennan; Lucy C Chappell Journal: PLoS One Date: 2013-10-10 Impact factor: 3.240
Authors: Fernanda Regina Giachini; Carlos Galaviz-Hernandez; Alicia E Damiano; Marta Viana; Angela Cadavid; Patricia Asturizaga; Enrique Teran; Sonia Clapes; Martin Alcala; Julio Bueno; María Calderón-Domínguez; María P Ramos; Victor Vitorino Lima; Martha Sosa-Macias; Nora Martinez; James M Roberts; Carlos Escudero Journal: Curr Hypertens Rep Date: 2017-10-06 Impact factor: 5.369